Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer.
Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Bhagia P, Cao ZA, Lunceford J, Suryawanshi S, Ayers M, J Marton M, Kato K. Shah MA, et al. Among authors: tajika m. Future Oncol. 2022 Jul 19. doi: 10.2217/fon-2021-1134. Online ahead of print. Future Oncol. 2022. PMID: 35852104
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.
Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Liu Q, Lunceford J, Kang SP, Bhagia P, Kato K. Shah MA, et al. Among authors: tajika m. JAMA Oncol. 2019 Apr 1;5(4):546-550. doi: 10.1001/jamaoncol.2018.5441. JAMA Oncol. 2019. PMID: 30570649 Free PMC article. Clinical Trial.
Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma.
Habu T, Kumanishi R, Ogata T, Fujisawa T, Mishima S, Kotani D, Kadowaki S, Nakamura M, Hojo H, Fujiwara H, Kumagai S, Koyama S, Fujita T, Kinoshita T, Nishikawa H, Yano T, Tajika M, Muro K, Mitsunaga S, Kojima T, Bando H. Habu T, et al. Among authors: tajika m. Esophagus. 2023 Jul;20(3):533-540. doi: 10.1007/s10388-023-00987-0. Epub 2023 Feb 8. Esophagus. 2023. PMID: 36750480
Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer.
Narita Y, Kadowaki S, Masuishi T, Taniguchi H, Takahari D, Ura T, Ando M, Tajika M, Niwa Y, Eto T, Hara H, Asayama M, Yamaguchi K, Yatabe Y, Muro K. Narita Y, et al. Among authors: tajika m. Oncol Lett. 2017 Aug;14(2):2545-2551. doi: 10.3892/ol.2017.6409. Epub 2017 Jun 19. Oncol Lett. 2017. PMID: 28781693 Free PMC article.
Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.
Komori A, Taniguchi H, Hamauchi S, Masuishi T, Kito Y, Narita Y, Tsushima T, Ishihara M, Todaka A, Tanaka T, Yokota T, Kadowaki S, Machida N, Ura T, Fukutomi A, Ando M, Onozawa Y, Tajika M, Yasui H, Muro K, Mori K, Yamazaki K. Komori A, et al. Among authors: tajika m. Oncology. 2017;93(5):329-335. doi: 10.1159/000479280. Epub 2017 Sep 2. Oncology. 2017. PMID: 28866662
The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma.
Matsubara Y, Toriyama K, Kadowaki S, Ogata T, Nakazawa T, Kato K, Nozawa K, Narita Y, Honda K, Masuishi T, Bando H, Ando M, Tajika M, Oze I, Hosoda W, Muro K. Matsubara Y, et al. Among authors: tajika m. Esophagus. 2023 Jul;20(3):524-532. doi: 10.1007/s10388-022-00978-7. Epub 2023 Jan 3. Esophagus. 2023. PMID: 36595124
234 results